Sármay G, Koncz G, Pecht I, Gergely J
Department of Immunology, Loránd Eötvös University, Göd, Hungary.
Immunol Lett. 1999 May 3;68(1):25-34. doi: 10.1016/s0165-2478(99)00026-7.
Co-clustering B cell receptors (BCR) and type II receptors binding the Fc part of IgG (Fc gamma RIIb) inhibits B cell activation and antibody production. Tyrosine phosphorylation of an intracellular motif of Fc gamma RIIb has been shown to be a prerequisite of the inhibition. After being phosphorylated by BCR-activated tyrosine kinases, the immunoreceptor tyrosine-based inhibitory motif (P-ITIM) of Fc gamma RIIb recruits SH2 domain containing protein tyrosine phosphatase(s) (PTPs) and polyphosphoinositol 5-phosphatase (SHIP) to the vicinity of BCR, which in turn dephosphorylate their specific substrates. This leads to the interruption of signal transduction, consequently to the anergy and/or apoptosis of the cell. The downstream signaling pathways affected by Fc gamma RIIb-BCR co-clustering are not clarified yet, neither the substrates of PTPs are known. We have studied the Fc gamma RIIb mediated B cell inhibition on human Burkitt lymphoma cell line (BL41). From the lysates of BL41 cells SHP-2 and phosphatidylinositol 3-kinase (PI3-K), as well as the protein tyrosine kinase (PTK) Lyn bind both to the BCR-co-clustered Fc gamma RIIb and to its P-ITIM peptide. Lyn hyperphosphorylates the P-ITIM associated molecules, including SHIP in the in vitro protein tyrosine kinase activity assay. The P-ITIM-compelled multi-phosphoprotein complex binds to and activates SHP-2, which in turn dephosphorylates SHIP and Shc and probably other substrates. Subcellular localisation of these signaling molecules is regulated by the phosphotyrosine-SH2 domain interactions, thus dephosphorylation may result in the re-direction of Shc and SHIP within the cell, consequently, in the modulation of their activity. Finally, co-clustering Fc gamma RIIb and BCR or Fc gamma RIIb and CD19 on the intact cells inhibited PI3-K activity as detected in the anti-phosphotyrosine (anti-PY) precipitates. The results indicate that SHP-2 bound to and activated by the BCR co-clustered Fc gamma RIIb, may down-regulate PI3-K activity by dephosphorylating a yet unidentified regulatory molecule, which recruits PI3-K to the cell membrane.
B细胞受体(BCR)与结合IgG Fc部分的II型受体(FcγRIIb)共聚类可抑制B细胞活化和抗体产生。FcγRIIb细胞内基序的酪氨酸磷酸化已被证明是这种抑制作用的前提条件。在被BCR激活的酪氨酸激酶磷酸化后,FcγRIIb的基于免疫受体酪氨酸的抑制基序(P-ITIM)招募含SH2结构域的蛋白酪氨酸磷酸酶(PTP)和多磷酸肌醇5-磷酸酶(SHIP)至BCR附近,进而使其特定底物去磷酸化。这导致信号转导中断,从而导致细胞无反应性和/或凋亡。FcγRIIb-BCR共聚类影响的下游信号通路尚未阐明,PTP的底物也未知。我们研究了FcγRIIb介导的对人伯基特淋巴瘤细胞系(BL41)的B细胞抑制作用。从BL41细胞裂解物中发现,SHP-2和磷脂酰肌醇3-激酶(PI3-K)以及蛋白酪氨酸激酶(PTK)Lyn既与BCR共聚类的FcγRIIb结合,也与它的P-ITIM肽结合。在体外蛋白酪氨酸激酶活性测定中,Lyn使包括SHIP在内的与P-ITIM相关的分子过度磷酸化。P-ITIM诱导的多磷酸蛋白复合物与SHP-2结合并激活SHP-2,SHP-2进而使SHIP和Shc以及可能的其他底物去磷酸化。这些信号分子的亚细胞定位受磷酸酪氨酸-SH2结构域相互作用调节,因此去磷酸化可能导致Shc和SHIP在细胞内重新定位,从而调节它们的活性。最后,在完整细胞上FcγRIIb与BCR或FcγRIIb与CD19共聚类可抑制抗磷酸酪氨酸(抗-PY)沉淀中检测到的PI3-K活性。结果表明,与BCR共聚类的FcγRIIb结合并激活的SHP-2可能通过使一个尚未确定的调节分子去磷酸化来下调PI3-K活性,该调节分子将PI3-K招募至细胞膜。